Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA… Recruiting

2022-501866-22-00 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 2025-08-26
A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia Recruiting

2024-518502-40-00 Immune Thrombocytopenia 2025-07-28
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed A… Recruiting

2023-509212-29-01 Patients (male or female) ≥18 years old with R/R AML th 2025-07-10
Phase 1b/2a clinical trial to determine the safety, tolerability and efficacy of TZ-161 in Spinal Cord Injury Recruiting

2023-509207-33-01 Early acute spinal cord injury 2025-07-09
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting

2024-517819-74-00 Pancreatic Ductal Adenocarcinoma 2025-06-02
Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early-stage NSC… Recruiting

2024-516580-87-00 early stage NSCLC 2024-10-29
A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS) Recruiting

2023-509872-41-00 congenital neuromuscular disorders 2024-09-24
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 LA/mGC/GEJC (locally advanced unresectable or metastati 2024-08-16
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 gastroesophageal junction adenocarcinoma 2024-08-05
Comparison of the efficacy of standard treatment associated with phage therapy versus standard treatment plus placebo for diabetic foot ulce… Recruiting

2022-500541-24-00 Diabetic foot 2024-07-02
VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting

2022-503055-26-00 Unresectable recurrent or metastatic HPV16 (Human Papil 2023-10-30
Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting

2023-506464-14-00 Advanced solid tumors 2023-06-29
A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting

2023-510275-64-00 Hepatocellular carcinoma, colorectal cancer, endometria 2023-05-31
A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting

2022-500391-62-00 Subjects with relapsed/refractory peripheral T-cell lym 2023-01-19
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting

2024-513185-19-00 Extensive stage small cell lung cancer (ES-SCLC) 2022-07-13
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Relapsed and/or Refractory Chronic Lymphocytic Leukemia 2021-12-20
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T… Recruiting

2023-504084-17-00 ALK fusion-positive extracranial solid or primary CNS t 2021-07-12
A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting

2023-506838-68-00 Renal cell carcinoma 2020-12-10
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib … Recruiting

2024-512972-36-00 Indolent B-Cell Non-Hodgkin Lymphoma 2019-05-23
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 pediatric CD22-positive relapsed/refractory Acute Lymph 2017-01-13
Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN) Recruiting

2025-524279-22-00 Spinal cord injury 2026-05-22
A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting

2025-523602-33-00 Advanced or unresectable Hepatocellular Carcinoma (HCC) 2026-05-13
Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory… Recruiting

2025-521420-30-00 Inflammatory Bowel Disease (IBD) 2026-05-08
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting

2024-515770-27-00 Multiple Myeloma 2026-04-27